E6446

E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD) -fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) [1][2][3].

Product Specifications

CAS Number

[1219925-73-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Stearoyl-CoA Desaturase (SCD) ; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/e6446.html

Concentration

10mM

Purity

98.78

Solubility

DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C1(C2=CC=C(OCCCN3CCCC3)C=C2)=NC4=CC=C(OCCCN5CCCC5)C=C4O1

Molecular Formula

C27H35N3O3

Molecular Weight

449.59

Precautions

H302, H315, H319, H335

References & Citations

[1]Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85 (3) :429-40.|[2]Franklin BS, et al. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc Natl Acad Sci U S A. 2011 Mar 1;108 (9) :3689-94.|[3]Wang W, et al. Identification of novel SCD1 inhibitor alleviates nonalcoholic fatty liver disease: critical role of liver-adipose axis. Cell Commun Signal. 2023 Sep 30;21 (1) :268.